Scholars Central

Conference abstractPublished 20 Oct 2014

MDM2 Mediated cancer angiogenesis and novel anti-angiogenic agents

Authors: Appu Rathinavelu

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Angiogenesis plays a very important role in controlling the tumor growth and metastatic progression. Evidently, the angiogenic mechanisms are often regulated by the microenvironment that surrounds the tumor, thorough the use of hypoxia inducible transcription control process and release of growth factors such as VEGF. Though the tumor angiogenesis is regulated by a wide range of intracellular mechanisms, the role for MDM2 in controlling tumor angiogenesis and metastasis has been slowly evolving. Our recent studies have established a strong link between MDM2 and VEGF transcription control mechanisms. Also, interference with the function of the Vascular Endothelial Growth Factor Receptor (VEGFR) has become one of the main strategies to obstruct tumor growth by blocking pro-angiogenic signals. In this respect, several anti-angiogenic blockers are currently available with a wide range of specificities and mechanisms. Many of these anti-angiogenic drugs are either monoclonal antibodies with certain specificity towards neutralizing pro-angiogenic factors or small molecules with an ability to block VEGFR related kinases. However, through molecular modeling approach two new anti-angiogenic drugs were designed at the Rumbugh Goodwin Institute for Cancer Research of NSU to interfere with the binding sites of VEGFR rather than inhibiting the receptor associated kinases. A novel isoindol-amide compound code named F16 and a second compound with a structure that is analogous to purine moiety were identified as new competitive antagonists for VEGF. Both the F16 and JFD have strong anti-angiogenesis potentials since different concentrations (0 to 10 μM) of the experimental drugs can inhibit the tube formation by HUVEC cells on EC-MatrixTM gel. Receptor binding assay with Fluorokine conjugated VEGF in HUVEC cells has also confirmed a strong competitive binding ability for both F16 and JFD (0.001 to 1.0 μM) in a dose dependent manner. The new drugs also show strong anti-cancer effects in athymic nude mice that are implanted with GI-101A breast tumor. Interestingly, the combination treatment with Taxol was more effective in the xenograft tumor model compared to mono-therapies with F16, JFD or Taxol alone. Results so far clearly suggests that F16 and JFD can specifically inhibit VEGF binding to VEGFR2 and reduce phosphorylation that can eventually prevent endothelial cell proliferation and tumor angiogenesis. Furthermore, the results from the in vivo experiments are very conclusive and support the fact that these two small molecules can inhibit tumor growth by blocking VEGFR. At present both in vitro and in vivo experimental results are strong enough to validate F16 and JFD as promising anti-angiogenic agents with significant therapeutic potential.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Appu Rathinavelu”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels